26 ANTI-AGING
Figure 7: Crow’s feet image with PRIMOS of a volunteer of 45 years old with an improvement in wrinkle volume of 32.0% after applying 3% Munapsys before (left) and after 7 days (right). Volunteer of the panel that applied 3% Munapsys and 5% benchmarks.
Roughness and wrinkles were assessed by PRIMOS and VISIA.
The botulinum toxin-like peptide always showed better results than placebo obtaining improvements of 7%, 10% and 7% in average roughness (Ra), average relief (Rz) and maximum relief height (Rt), after 14 days (Fig 4). In addition, the botulinum toxin-like peptide presented significant values in the three parameters of roughness and in maximum wrinkle depth at the end of the study (Fig 5). In addition, the group of volunteers that used 3% botulinum toxin-like peptide and 5% benchmark experienced a higher improvement in wrinkle reduction with a lower dose of the botulinum toxin-like peptide than with the benchmark (Fig 6 and Fig 7). This suggests a higher efficacy of the botulinum toxin-like peptide than of the benchmark combination. Moreover, in almost all the tested parameters there were more volunteers responding to the cream with 3% botulinum toxin-like peptide than with the 5% benchmark. We can hypothesize that if there are more volunteers responding, it could be translated into more satisfied users.
Lifting sad smiles
A panel of female volunteers presenting a sad smile (drooping corners of the mouth), between 35 and 55 years old, applied a cream with 3% botulinum toxin-like peptide on the face for 28 days. The lifting of lip’s commissures was evaluated by clinical grading.
At the end of the study, 33% of volunteers
presented an average lifting of commissures of 14%, showing a happier smile (Fig 8).
Conclusion
Munapsys demonstrated action on both pre- and post-synaptic pathways. It competed against Munc18-1 for its binding with syntaxin which is essential for the SNARE formation and it reduced the levels of ACh release by the pre-synaptic vesicles in the neuron. It also acted on AChR clustering, muscle membrane depolarization, calcium mobilisation and actomyosin cross-bridge and sliding. Finally, its efficacy as a wrinkle smoother was evaluated against a combination of benchmarks (covering both pathways) and proved to be similar or better at a lower concentration. In addition, Munapsys also presented good results in the lifting of sad smiles. We conclude that Munapsys could be
considered a real upgrade in the botulinum toxin-like ingredients field.
PC
References 1 Zhou P, Pang ZP, Yang X, et al. Syntaxin-1 N-
peptide and Habc-domain perform distinct essential functions in synaptic vesicle fusion. EMBO J. 32(1):159-71, 2012.
2 Kavanagh DM, Smyth AM, Martin KJ, et al. A molecular toggle after exocytosis sequesters the presynaptic syntaxin1a molecules involved in prior vesicle fusion. Nat Commun. 5:5774, 2014.
3 Ma L, Rebane AA, Yang G, et al. Munc18-1- regulated stage-wise SNARE assembly underlying synaptic exocytosis. eLife. 4:e09580, 2015.
4 Huh KH, Fuhrer C. Clustering of nicotinic acetylcholine receptors: from the neuromuscular junction to interneuronal synapses. Mol Neurobiol. 25(1):79-112, 2002.
5 Banks GB, Fuhrer C, Adams ME, et al. The postsynaptic submembrane machinery at the neuromuscular junction: requirement for rapsyn and the utrophin/dystrophin-associated complex. J Neurocytol. 32(5-8):709-26, 2003.
6 Ruff RL. Endplate contributions to the safety factor for neuromuscular transmission. Muscle Nerve. 44(6):854-61, 2011.
7 Krans, J.
L.The Sliding Filament Theory of Muscle Contraction. Nature Education 3(9):66, 2010.
T0 days
T28 days
Figure 8: Images of a volunteer of 51 years old that improved the dropping of the commissures by 16.7% after applying a cream with 3% Munapsys before (left) and after 28 days (right).
PERSONAL CARE NORTH AMERICA May 2019
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
